Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Ono Pharmaceutical Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 2/6

Ono Pharmaceutical yıllık ortalama 18.2% oranında kazançlarını artırırken, Pharmaceuticals sektöründe kazançlar growing at 5.4% annual. Gelirler growing yılda ortalama 13.5% oranında artmaktadır. Ono Pharmaceutical'in özkaynak karlılığı 14.8% ve net marjı 24.2%'dir.

Anahtar bilgiler

18.2%

Kazanç büyüme oranı

19.4%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	3.4%
Gelir büyüme oranı	13.5%
Özkaynak getirisi	14.8%
Net Marj	24.2%
Sonraki Kazanç Güncellemesi	31 Oct 2024

Yakın geçmiş performans güncellemeleri

Recent updates

We Think Ono Pharmaceutical (TSE:4528) Can Stay On Top Of Its Debt

Aug 25

Ono Pharmaceutical Co., Ltd. (TSE:4528) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Aug 04

There's No Escaping Ono Pharmaceutical Co., Ltd.'s (TSE:4528) Muted Earnings

Jun 24

Ono Pharmaceutical (TSE:4528) Has Announced A Dividend Of ¥40.00

Mar 04

Is There An Opportunity With Ono Pharmaceutical Co., Ltd.'s (TSE:4528) 42% Undervaluation?

Feb 27

Gelir ve Gider Dağılımı

Ono Pharmaceutical nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

TSE:4528 Gelir, gider ve kazançlar (JPY Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	500,331	120,953	101,792	116,452
31 Mar 24	502,672	127,977	97,389	112,174
31 Dec 23	498,070	127,611	93,791	105,863
30 Sep 23	489,199	124,875	91,302	105,076
30 Jun 23	460,481	115,064	88,400	100,510
31 Mar 23	447,187	112,723	86,643	95,344
31 Dec 22	428,951	111,555	82,778	92,389
30 Sep 22	403,985	96,568	79,408	82,955
30 Jun 22	380,720	85,922	76,890	80,047
31 Mar 22	361,361	80,519	74,119	75,879
31 Dec 21	345,781	73,558	75,888	68,001
30 Sep 21	332,887	81,866	74,455	69,203
30 Jun 21	321,734	78,003	71,372	65,286
31 Mar 21	309,284	75,425	66,616	62,384
31 Dec 20	302,054	74,364	62,474	64,973
30 Sep 20	293,886	66,737	61,279	61,295
30 Jun 20	293,351	64,870	62,822	62,874
31 Mar 20	292,420	59,704	65,196	66,497
31 Dec 19	290,736	60,233	66,771	64,207
30 Sep 19	293,247	55,510	67,528	67,895
30 Jun 19	291,374	52,633	67,548	70,264
31 Mar 19	288,634	51,539	68,000	70,008
31 Dec 18	284,463	51,978	69,043	71,627
30 Sep 18	284,785	57,919	67,967	70,453
30 Jun 18	272,165	53,746	67,138	69,593
31 Mar 18	261,836	50,284	66,353	68,821
31 Dec 17	256,522	54,760	64,978	66,892
30 Sep 17	248,517	53,884	63,966	63,599
30 Jun 17	246,953	53,887	62,846	61,325
31 Mar 17	244,797	55,793	60,660	57,506
31 Dec 16	236,710	48,270	57,396	52,949
30 Sep 16	207,707	36,225	53,702	49,595
30 Jun 16	183,345	29,206	49,850	46,653
31 Mar 16	160,284	24,979	42,628	43,369
31 Dec 15	140,927	16,449	38,705	40,751
30 Sep 15	143,697	21,568	37,113	40,790
30 Jun 15	139,663	19,521	36,244	39,972
31 Mar 15	135,775	12,976	40,824	41,346
31 Dec 14	137,592	17,663	42,572	38,204
30 Sep 14	133,926	13,474	41,296	39,463
30 Jun 14	137,146	16,787	39,685	40,895
31 Mar 14	143,247	20,350	36,900	44,413
31 Dec 13	145,946	21,574	35,552	49,229

Kaliteli Kazançlar: 4528 yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: 4528 'nin mevcut net kar marjları (24.2%) geçen yılın (25%) değerinden daha düşüktür.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 4528 şirketinin kazancı son 5 yılda yılda 18.2% oranında arttı.

Büyüme Hızlandırma: 4528 'un son bir yıldaki kazanç büyümesi ( 5.1% ) 5 yıllık ortalamasının ( 18.2% /yıl) altındadır.

Kazançlar vs. Sektör: 4528 geçen yılki kazanç büyümesi ( 5.1% ) Pharmaceuticals sektörünün 8.6% performansını geride bırakmadı.

Özkaynak Getirisi

Yüksek ROE: 4528 'nin Özsermaye Getirisi ( 14.8% ) düşük olarak değerlendiriliyor.

Ono Pharmaceutical Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 2/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Ono Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Oct 31, 2024

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2024 earnings: EPS and revenues miss analyst expectations

Ono Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Jul 31, 2024

Full year 2024 earnings: EPS and revenues miss analyst expectations

Ono Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 09, 2024

Recent updates

Upcoming dividend of JP¥40.00 per share

We Think Ono Pharmaceutical (TSE:4528) Can Stay On Top Of Its Debt

Ono Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Oct 31, 2024

Ono Pharmaceutical Co., Ltd. Announces U.S. Food and Drug Administration Accepts for Priority Review Deciphera’s New Drug Application for Vimseltinib for the Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)

Ono Pharmaceutical Co., Ltd. (TSE:4528) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

European Medicines Agency Accepts Deciphera's Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)

Final dividend of JP¥40.00 announced

Consensus EPS estimates fall by 23%

Full year 2024 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

There's No Escaping Ono Pharmaceutical Co., Ltd.'s (TSE:4528) Muted Earnings

Price target decreased by 10% to JP¥2,336

Ono Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Jul 31, 2024

Ono Pharmaceutical Co., Ltd. (TSE:4528) completed the acquisition of Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) from BlackRock, Inc. (NYSE:BLK), Deerfield Capital, L.P., Redmile Group, LLC Brightstar Associates, LLC and others.

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 10%

Full year 2024 earnings: EPS and revenues miss analyst expectations

Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 20, 2024

Ono Pharmaceutical Co., Ltd. (TSE:4528) entered into a definitive merger agreement to acquire Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) for $2.2 billion.

Ono Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 09, 2024

ONO Pharmaceuticals, Co., Ltd. Announces Enrollment is Complete for the First Arm of the PROSPECT Study of Tirabrutinib in U.S. Patients with Relapsed or Refractory PCNSL

Upcoming dividend of JP¥40.00 per share

Ono Pharmaceutical (TSE:4528) Has Announced A Dividend Of ¥40.00

Is There An Opportunity With Ono Pharmaceutical Co., Ltd.'s (TSE:4528) 42% Undervaluation?

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Ono Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Jan 31, 2024

Price target increased by 7.4% to JP¥2,935

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Upcoming dividend of JP¥40.00 per share at 2.8% yield

Ono Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 01, 2023

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Ono Pharmaceutical Co., Ltd. (TSE:4528) announces an Equity Buyback for 19,000,000 shares, representing 3.89% for ¥50,000 million.

Now 20% undervalued after recent price drop

Ono Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023

Now 21% undervalued after recent price drop

Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 22, 2023

Full year 2023 earnings: EPS misses analyst expectations

Upcoming dividend of JP¥33.00 per share at 2.4% yield

Price target decreased by 7.4% to JP¥3,292

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ono Pharmaceutical Co., Ltd. (TSE:4528) acquired Research assets related to multiple research-stage oncology programs from KSQ Therapeutics, Inc.

Ono Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Jan 31, 2023

Less than half of directors are independent

Second quarter 2023 earnings: EPS exceeds analyst expectations

Upcoming dividend of JP¥33.00 per share

Ono Pharmaceutical Co., Ltd. to Report Q2, 2023 Results on Oct 31, 2022

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 21% undervalued

Ono Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Aug 01, 2022

Full year 2022 earnings: EPS misses analyst expectations

Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2022

Consensus EPS estimates fall by 11%

Now 21% undervalued

Less than half of directors are independent

Ono Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on May 11, 2022

Upcoming dividend of JP¥28.00 per share

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ono Pharmaceutical Co., Ltd. (TSE:4528) announces an Equity Buyback for 11,000,000 shares, representing 2.2% for ¥30,000 million.

Second quarter 2022 earnings released: EPS JP¥44.51 (vs JP¥36.77 in 2Q 2021)

Upcoming dividend of JP¥28.00 per share

Exelixis, Inc. Announces Partner Takeda Pharmaceutical Company Limited and Ono Receive Approval in Japan for CABOMETYX in Combination with Opdivo for the Treatment of Unresectable or Metastatic Renal Cell Carcinoma

First quarter 2022 earnings released: EPS JP¥48.23 (vs JP¥43.07 in 1Q 2021)

Full year 2021 earnings released: EPS JP¥151 (vs JP¥118 in FY 2020)

Full year 2021 earnings released: EPS JP¥151 (vs JP¥118 in FY 2020)

Upcoming dividend of JP¥22.50 per share

Ono Pharmaceutical Co., Ltd. to Report Fiscal Year 2021 Results on May 11, 2021

New 90-day low: JP¥3,020

Third quarter 2021 earnings released: EPS JP¥53.37 (vs JP¥38.09 in 3Q 2020)